Skip to main content
main-content

21.07.2022 | COVID-19 | Research

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis

verfasst von: Diogo Martins-Branco, Guilherme Nader-Marta, Ana Tecic Vuger, Veronique Debien, Lieveke Ameye, Mariana Brandão, Kevin Punie, Angela Loizidou, Karen Willard-Gallo, Chloe Spilleboudt, Ahmad Awada, Martine Piccart, Evandro de Azambuja

Erschienen in: Journal of Cancer Research and Clinical Oncology

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This systematic review and meta-analysis aimed to evaluate the immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer.

Methods

We performed a systematic literature search using PubMed, Embase, and Cochrane Library until 28/09/2021, and conference proceedings from ASCO and ESMO 2021 annual meetings. We screened for observational or interventional studies including subjects ≥ 16 years old with cancer diagnosis who were vaccinated against SARS-CoV-2. Prime-vaccination was defined as one dose of Ad26.COV2-S vaccine or two doses of BNT162b2, mRNA-1273, ChAdOx1-S or inactivated SARS-CoV-2 vaccine. The outcomes were humoral and adaptive immune responses (proportion of subjects with positive titers of antibody anti-SARS-CoV-2 spike protein and anti-SARS-CoV-2 cellular responses, respectively).

Results

We included 89 records reporting data from 30,183 subjects. The overall seropositive rate within the first month after complete anti-SARS-CoV-2 prime-vaccination was 80% [95% confidence interval (CI), 72–86%], 60% (95%CI, 53–67%) in patients with hematological malignancies (HM) versus 94% (95%CI, 88–97%) in patients with solid malignancies (SM). The diagnosis of HM was significantly associated with a lower seropositive rate on multivariate meta-regression (odds ratio 0.35, 95% CI 0.18–0.69, HM versus both, p = 0.002). The overall humoral response was 49% (95% CI, 42–56%) after incomplete prime-vaccination and 79% (95% CI, 70–86%) at 2 months after complete prime-vaccination. These responses were also lower in patients with HM at these time points. The overall cellular response rate at any time after vaccination was 61% (95% CI, 44–76%).

Conclusion

This meta-analysis provides compelling evidence of humoral and adaptive immune responses against SARS-CoV-2 in patients with cancer, which last for at least 2 months following complete prime-vaccination.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Metadaten
Titel
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis
verfasst von
Diogo Martins-Branco
Guilherme Nader-Marta
Ana Tecic Vuger
Veronique Debien
Lieveke Ameye
Mariana Brandão
Kevin Punie
Angela Loizidou
Karen Willard-Gallo
Chloe Spilleboudt
Ahmad Awada
Martine Piccart
Evandro de Azambuja
Publikationsdatum
21.07.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-022-04185-w

Corona-Update

Die aktuelle Entwicklung im Überblick: Nachrichten, Webinare, Übersichtsarbeiten.

Passend zum Thema

ANZEIGE

Fragen und Antworten zur COVID-19-Impfung

In diesem Beitrag finden Sie Antworten auf häufig gestellte Fragen zu den Coronaimpfungen. Beantwortet von Prof. Dr. med. Ulrich Heininger, Basel.

ANZEIGE

Dysphagie Screening Tool Geriatrie (DSTG)

Ende 2019 ist das neue Dysphagie Screening Tool Geriatrie (DSTG) der AG Dysphagie der Deutschen Gesellschaft für Geriatrie (DGG) erschienen.

ANZEIGE

consilium – Expertenwissen zu Themen aus dem Praxisalltag der Allgemeinmedizin und der Geriatrie

Das consilium Allgemeinmedizin/Geriatrie von InfectoPharm vermittelt Ihnen Expertenwissen zu Themen aus Ihrer alltäglichen Praxis. Dabei geht es in der Regel um aktuelle spannende Patientenfälle, relevante Therapiefragen oder Fragen zu geeigneten diagnostischen Maßnahmen sowie möglichen Differenzialdiagnosen. Machen Sie sich selbst ein Bild!